Artificial Disk Meets Reimbursement Resistance 3787Artificial Disk Meets Reimbursement Resistance 3787
March 1, 2005
Originally Published MX March/April 2005
BUSINESS NEWS
The Charité artificial disk by DePuy Spine Inc. (Raynham, MA), a Johnson & Johnson company.Photo courtesy DePuy Spine |
When FDA approved the Charité artificial disk last October, some industry analysts speculated that the device could experience a rapid rate of adoption similar to those experienced by new joint-replacement technologies or drug-eluting coronary stents. To clinch their case, the experts cited pent-up demand for the device, which has been available to patients around the world for more than 17 years; the incidence of 200,000 spinal fusion surgeries performed each year in the United States; and the estimated $50 billion spent annually to treat back pain.
You May Also Like